explore -WSS

explore

author：Wikipedia 2025-09-30 20:47:20 - browse：5

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Results on Novartis prostate cancer therapy could expand its use

WSS

Elevance PBM president out as customers face prescription chaos

Roche drug slashes death risk in early

ADCs take center stage as promising cancer treatments

The most pressing bird flu mysteries scientists want answered

Elevance PBM president out as customers face prescription chaos

CMS got Medicare Advantage quality rating wrong, judge rules

Wikipedia

explore

hotspot

Medicare details structure of new drug price negotiation program

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Medical leaders decry Supreme Court decision on affirmative action

An outdated Medicare rule harms dementia patients with anxiety

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Continuity nursing helped my family in our darkest PICU moments

STAT Summit: The economic case for universal basic health care

Trump demands the U.S. pay no more for drugs than other countries … again

Anthony Fauci pushes back on GOP claims during Covid hearing

entertainment

Stopping antidepressants leads to symptoms for 1 in 6 patients

Take antibiotics after sex, CDC recommends for certain risk groups

Illumina board agrees to spin off Grail, as divestment plans proceed

CMS got Medicare Advantage quality rating wrong, judge rules

Why a market frenzy over new weight loss drugs defies logic

STAT Readout Newsletter: Biotech news today

leisure time

focus

explore

explore